
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934

For the Month of March, 2018

Commission File Number: 001-35892

GW PHARMACEUTICALS PLC

(Translation of registrant's name into English)

Sovereign House
Vision Park
Histon
Cambridge CB24 9BZ
United Kingdom

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes

No

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes

No

Notification of Interests Of Directors, Officers And Connected Persons

GW Pharmaceuticals plc (the "Company") hereby provides notification that on March 8, 2018, Adam George, Company Secretary and UK Managing Director exercised options under the Company's Long Term Incentive Plan and sold 17,200 American Depositary Shares ("ADSs") at a price of \$116.67 per ADS in accordance with his Rule 10b5-1 plan established February 14, 2018. Further details are set forth in the table below.

1.	Details of the person discharging managerial responsibilities / person closely associated		
a.	Name	Adam George	
2.	Reason for the notification		
a.	Position/status	UK Managing Director	
b.	Initial notification /Amendment	Initial notification	
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a.	Name	GW Pharmaceuticals PLC	
b.	LEI		
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a.	Description of the Financial instrument, type of instrument Identification code	American Depositary Shares ISIN: 36197T1034	
b.	Nature of the transaction	Exercise of Long Term Incentive Plan options and sale of resulting American Depositary Shares in accordance with 10b5.1 plan dated 14 February 2018	
c.	Price(s) and volume(s)	Price(s) \$116.67	Volume(s) 17,200 ADS's sold
d.	Aggregated information • <i>Aggregated volume</i> • <i>Price</i>	n/a	
e.	Date of the transaction	March 8, 2018	
f.	Place of the transaction	Nasdaq, New York	

For further information, please contact:

GW Pharmaceuticals PLC
Adam George, Company Secretary

+44 (0)1980 557 000

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

GW Pharmaceuticals plc

By: /s/ Adam George

Name: Adam George

Title: Company Secretary

Date: March 13, 2018
